3.8 Article

Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I

期刊

RARE DISEASES
卷 4, 期 1, 页码 -

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/21675511.2016.1225644

关键词

alternative splicing; Alu elements; disease modifiers; Myotonic Dystrophy Type I; pre-mRNA splicing; Stau1binding sites; Staufen1

资金

  1. Muscular Dystrophy Association [294865]
  2. Association Francaise contre les Myopathie [18285]
  3. Canadian Institute of Health Research via Canadian Muscular Dystrophy Association
  4. Rachel Fund for Myotonic Dystrophy
  5. University of Ottawa Brain and Mind Research Institute Center
  6. Translational Research Award
  7. Queen Elizabeth II Graduate Scholarship
  8. CIHR

向作者/读者索取更多资源

In a recent issue of PLOS Genetics, we reported that the double-stranded RNA-binding protein, Staufen1, functions as a disease modifier in the neuromuscular disorder Myotonic Dystrophy Type I (DM1). In this work, we demonstrated that Staufen1 regulates the alternative splicing of exon 11 of the human Insulin Receptor, a highly studied missplicing event in DM1, through Alu elements located in an intronic region. Furthermore, we found that Staufen1 overexpression regulates numerous alternative splicing events, potentially resulting in both positive and negative effects in DM1. Here, we discuss our major findings and speculate on the details of the mechanisms by which Staufen1 could regulate alternative splicing, in both normal and DM1 conditions. Finally, we highlight the importance of disease modifiers, such as Staufen1, in the DM1 pathology in order to understand the complex disease phenotype and for future development of new therapeutic strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据